Episodi

  • S8 Ep2: Mariska Hargitay Talks About Her Father's Myeloma

    S8 Ep2: Mariska Hargitay Talks About Her Father's Myeloma
    Sep 8 2026

    Actor and advocate Mariska Hargitay has partnered with Bristol Myers Squibb to launch "Investigating Myeloma," a disease awareness campaign honoring the 20th anniversary of her father Mickey Hargitay's death from multiple myeloma.

    The campaign spotlights the critical unmet needs in myeloma and highlights BMS's CELMoD research — an investigational approach that engages the cell's natural protein removal system to stimulate the immune system and enhance the killing of myeloma cancer cells — as a source of renewed hope for patients and their families.

    Hargitay spoke with CURE about her father's story, why she is speaking out now and what she wants patients to know today.
    Mostra di più Mostra meno
    7 min
  • S8 Ep1: Rob Lowe on His Grandmother's Cancer Journey and Why Clinical Trials Matter

    S8 Ep1: Rob Lowe on His Grandmother's Cancer Journey and Why Clinical Trials Matter
    Aug 31 2026

    In our season 8 premiere, actor and longtime breast cancer advocate Rob Lowe joins CURE Talks Cancer to share his grandmother's breast cancer journey, including the clinical trial that helped prolong her life after she was twice told to get her affairs in order. Rob talks about how watching her journey — alongside his mother's, great-grandmother's and father's own cancer experiences — shaped his family for generations, why he partnered with Lilly on a new clinical trial awareness campaign, and what he wishes every newly diagnosed patient knew before ruling a trial out.

    CURE Talks Cancer is a weekly podcast powered by CURE, on what we do best: Cancer Updates, Research and Education. Each week, you'll hear from patients, survivors, caregivers, advocates or health care professionals regarding the entire cancer continuum — ranging from specific cancer types to side effects to the psychological strains a cancer diagnosis can have on an individual and their loved ones.

    As the largest consumer magazine in the United States for patients, survivors and caregivers, we strive to combine science with humanity to make cancer understandable.

    To learn more, visit us on all socials!
    Mostra di più Mostra meno
    15 min
  • S7 Ep2: Breaking Down Metastatic Triple-Negative Breast Cancer Treatments

    S7 Ep2: Breaking Down Metastatic Triple-Negative Breast Cancer Treatments
    Dec 31 2025
    CURE sat down with Dr. Natalie S. Berger for the latest episode of the “Cancer Horizons” podcast to discuss frontline treatment options for patients with metastatic triple-negative breast cancer. Berger, who recently spoke at CURE’s Educated Patient® Metastatic Breast Cancer Summit, is an assistant professor of medicine at Columbia University Irving Medical Center Division of Hematology and Medical Oncology and the associate director of breast medical oncology at New York Presbyterian-Hudson Valley Hospital in New York.

    Key points discussed by Berger in the podcast included the importance of personalized medicine, with treatments tailored to tumor and patient characteristics. Immunotherapy, particularly Keytruda (pembrolizumab), is often used, especially for PDL-1 positive patients. PARP inhibitors are recommended for BRCA mutation-positive patients. Antibody-drug conjugates, like Trodelvy (sacituzumab govitecan), are emerging as effective treatments, shown to be superior to chemotherapy in combination with immunotherapy.

    Additionally, patients are encouraged to be active in their treatment decisions, engage in exercise and proper nutrition, and consider enrolling in clinical trials, while caregivers are advised to support patients by understanding their needs and providing appropriate assistance.
    Mostra di più Mostra meno
    15 min
  • S7 Ep1: The Importance of Spotting Endometrial Cancer

    S7 Ep1: The Importance of Spotting Endometrial Cancer
    Mar 18 2025
    Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
    Mostra di più Mostra meno
    10 min
  • S6 Ep23: ROS1+ Non-Small Cell Lung Cancer: Progress in Care

    S6 Ep23: ROS1+ Non-Small Cell Lung Cancer: Progress in Care
    Sep 17 2024
    20 min
  • S6 Ep22: Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

    S6 Ep22: Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine
    Mar 4 2024
    Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma. And finally, we’ll discuss another cancer vaccine clinical trial that got the green light from the Food and Drug Administration. FDA Approved Besponsa for Children With Acute Lymphoblastic LeukemiaThe first FDA approval of last week was one in the pediatric cancer space. The agency approved Besponsa for children who are at least 1 year old and have relapsed or refractory CD22-positive precursor acute lymphoblastic leukemia., also known as ALL. The approval is coming after findings from a single-arm study involving 53 children. Of which, 22 — that’s 42% — achieved a complete response from the therapy, with the median duration of complete response being 8.2 months. Additionally, the majority of patients who achieved a complete response also had minimal residual disease negativity, which indicates that there were 5% or less blasts found in the bone marrow and no cancer cells detected in the blood. Having a new treatment option for children with ALL is particularly exciting, as ALL is one of the most common pediatric cancers, according to the American Cancer Society. FDA Approves Opdivo Plus Chemo for Unresectable or Metastatic Bladder CancerLast week, the FDA also approved an immunotherapy/chemotherapy regimen for certain patients with bladder cancer. Specifically, the agency OKed Opdivo plus cisplatin and gemcitabine for the frontline treatment of adults with unresectable or metastatic urothelial carcinoma. This approval was backed by findings from the CheckMate-901 trial, which showed that the Opdivo-chemotherapy regimen improved overall survival (which is the time patients live before death of any cause) and progression-free survival (which is the time patients live without their disease worsening) compared to those who did not receive Opdivo. The median overall survival was 21.7 months for those who received Opdivo compared to 18.9 months for those who did not, while progression-free survival was 7.9 and 7.6 months, respectively. FDA Approves Brukinsa, Gazyva Combo for Relapsed, Refractory Follicular LymphomaLast week, the Food and Drug Administration also approved Brukinsa plus Gazyva for patients with relapsed or refractory follicular lymphoma after findings from the ROSEWOOD trial showed that not only did more patients respond to the two-drug treatment compared to Gazyva alone, but also at a median follow-up of 19 months, more patients were still responding compared to the Gazvya arm as well. Rhabdomyosarcoma Survivors May Have Poor Psychological OutcomesA study published in the journal, Cancer, found that survivors of rhabdomyosarcoma — which is a rare cancer affecting soft tissues — may face increased risk of psychological challenges, especially if they were exposed to previous radiation therapy or have a history of smoking.Researchers examined neurocognitive impairment, emotional distress and health-related quality of life in survivors compared to their siblings. Results showed higher rates of issues like memory impairment and emotional distress among survivors, with smoking linked to poorer outcomes. The CURE® team spoke with study author, Ellen van der Plas on the findings. Here is what she had to say. Ovarian Cancer Vaccine Trial Gets FDA Clearance to ProceedThe FDA has given the green light for a clinical trial of a vaccine designed to treat advanced ovarian cancer. Known as Innocell, this personalized therapy utilizes cells from the patient's own tumor which is inactivated via riboflavin and UV light. The drug is being manufactured at City of Hope in Los Angeles, and the trial aims to assess the vaccine's safety and effectiveness in stimulating immune response.This is one of the many cancer vaccines being explored and developed in the oncology space. Check back on prior CURE® coverage for updates on vaccines to treat breast, lung, skin and other cancers. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
    Mostra di più Mostra meno
    8 min
  • S6 Ep21: Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

    S6 Ep21: Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research
    Mar 4 2024
    In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them. We heard from an expert about using cannabis during cancer care, took a look at a patient population that may be more prone to cardiometabolic conditions after cancer treatment and we’ll highlight a study that’s looking at preventing infection and GVHD in patients with blood cancer who underwent a stem cell transplant. Patients Should ‘Have the Conversation’ About Cannabis With Care TeamsThe use of cannabis seems to be growing when it comes to mitigating side effects from cancer treatment, though it is important that patients talk to their providers if they are using these products or have questions about them, explained Dr. Brooke Worster from Thomas Jefferson University. I recently spoke to Woster about the conversations patients with cancer should be having if they’re using or considering using cannabis. Namely, she discussed seeking guidance and having open discussions with the care team, but also remembering that cannabis is not a proven cure for any kinds of cancer. Drug Gets Breakthrough Therapy Designation for HER2-Mutant Lung Cancer A novel drug, BAY 2927088 received a breakthrough therapy designation for treating HER2-mutant non-small cell lung cancer. This designation, granted by the FDA, signifies a potential advancement in treatment options for patients with this specific type of lung cancer, which happens in approximately 2% to 4% of advanced NSCLC cases. Now that the drug has a breakthrough therapy designation, its review will be fast tracked. BAY 2927088, an oral tyrosine kinase inhibitor, has shown promising results in a phase 1 trial, with a focus on safety, efficacy and patient outcomes. The drug works by blocking HER2, which can contribute to lung cancer proliferation. Hispanic/Latino Survivors May Be Higher Risk for Cardiometabolic ComorbiditiesA recent study found that Hispanic/Latino cancer survivors have higher rates of cardiometabolic comorbidities — meaning health conditions that affect the heart and/or metabolic system — such as diabetes, hypertension and heart disease, which can complicate cancer treatment and post-treatment health management. The study showed that survivors with cardiometabolic conditions experienced lower health-related quality of life and had unmet supportive care needs, particularly in terms of emotional and physical well-being. The research also found that socioeconomic factors, such as income levels, were also linked to the prevalence of cardiometabolic conditions among Hispanic/Latino survivors, highlighting the importance of access to health care and healthy lifestyle behaviors in managing these health challenges. The study emphasized the need for holistic approaches to health that consider environmental influences and support policies promoting heart-healthy behaviors within communities. Trial Evaluates Reduced Chemo Post-Stem Cell Transplant in Blood CancersPatients with blood cancers can talk to their cancer care team about possible enrollment in the OPTIMIZE trial, which is investigating a lower dose of post-transplant cyclophosphamide — also referred to as “PTCy” — to reduce infection risk post-stem cell transplant while preventing graft-versus-host disease in patients who underwent a stem cell transplant from a partially matched unrelated donor. This phase 2 trial aims to enroll 190 patients across cancer centers across the United States, and is expected to conclude in June 2026. By exploring reduced PTCy dosages, researchers hope to enhance patient survival and quality of life by minimizing toxicities associated with standard dosing. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
    Mostra di più Mostra meno
    10 min
  • S6 Ep20: FDA Approvals from February 2024

    S6 Ep20: FDA Approvals from February 2024
    Feb 23 2024
    Last week, the Food and Drug Administration (FDA) approved four different therapies in the oncology space — one of which, Amtagvi, marks the first cellular therapy for the treatment of solid cancers.


    The week’s first approval (an Onivyde regimen for metastatic pancreatic cancer) was covered in last week’s episode, but here’s a list of what has happened since that last recording.



    FDA Approves Tepmetko for Metastatic NSCLC Subtype


    Patients with metastatic non-small cell lung cancer that has MET exon 14 skipping alterations may soon have a new treatment option, as the FDA approved Tepmetko in this indication.


    Notably, this full approval is coming three years after the agency’s accelerated approval of the agent back in February 2021. Follow-up clinical trial data showed that 57% of previously untreated patients responded to therapy with Tepmetko, with 40% having a duration of response that lasted a year or longer.


    FDA Approves Amtagvi for Pretreated, Advanced Melanoma


    On Feb. 16, the FDA approved Amtagvi for patients with advanced melanoma who had previously been treated with an immunotherapy or targeted therapy. Notably, Amtagvi is a cell-based therapy and is actually the first cell-based treatment to be approved in the solid tumor space.


    According to trial results that led to the approval, 31.5% of patients responded to therapy. Now this is a pretty exciting number, considering that this heavily pretreated population tends to have low response rates. Not to mention, TIL therapies like Amtagvi — while upfront they require about a three-week hospital stay — may set patients up for years without having to undergo more treatment, according to Dr. Rodabe Amaria from The University of Texas MD Anderson Cancer Center, who I spoke with after the approval.



    Tagrisso Plus Chemo Approved by FDA for EGFR-Mutated NSCLC


    In the lung cancer space, we saw the approval of Tagrisso plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.


    Findings from the FLAURA 2 trial led to this approval, as data showed that progression-free survival was 25.5 months for patients who received Tagrisso plus chemotherapy, compared to 16.7 months for patients who received Tagrisso alone. Overall survival data is still immature at this point — meaning that the researchers just don’t have enough data to calculate averages — so stay tuned for more on that.

    For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
    Mostra di più Mostra meno
    6 min